Clinical trial simulations in pulmonary fibrosis: patient-focused insights and adaptations
Background Patient recruitment and retention are a challenge when conducting clinical trials in patients with pulmonary fibrosis, including idiopathic pulmonary fibrosis and other interstitial lung diseases. This study aimed to understand and address the barriers associated with trial participation...
Main Authors: | Steve Jones, Maxine Flewett, Ron Flewett, Sharon Lee, Bill Vick, Milla Thompson, Sabine Pinnetti, Donald F. Zoz, Anna-Maria Hoffmann-Vold, Michael Kreuter, Toby M. Maher |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2023-05-01
|
Series: | ERJ Open Research |
Online Access: | http://openres.ersjournals.com/content/9/3/00602-2022.full |
Similar Items
-
Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis
by: Toby M. Maher, et al.
Published: (2022-10-01) -
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
by: Toby M Maher, et al.
Published: (2023-11-01) -
Plain language summary: clinical trial of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis
by: Luca Richeldi, et al.
Published: (2022-12-01) -
Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial
by: Michael Kreuter, et al.
Published: (2023-03-01) -
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
by: Toby M Maher, et al.
Published: (2023-12-01)